Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 1,201–1,300 of 2,932
Fletcher, J., O’Connor-Moneley, J., Frawley, D., Flanagan, P. R., Alaalm, L., Menéndez-Manjón, P., Estevez, S. V., Hendricks, S., Woodruff, A. L., Buscaino, A., et al. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1011082 · Cited by 11
Hurraß, J., Heinzow, B., Walser‐Reichenbach, S., Aurbach, U., Becker, S., Bellmann, R., Bergmann, K., Cornely, O. A., Engelhart, S., Fischer, G., et al. (2024) · Pneumologie · doi:10.1055/a-2194-6914 · Cited by 11
Xie, F., Hao, Y., Liu, Y., Bao, J., Wang, R., Chi, X., Wang, T., Yu, S., Jin, Y., Li, L., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02292 · Cited by 11
Stephanoascus ciferrii Complex: The Current State of Infections and Drug Resistance in Humans
Cosio, T., Pica, F., Fontana, C., Pistoia, E. S., Favaro, M., Valsecchi, I., Zarabian, N., Campione, E., Botterel, F., & Gaziano, R. (2024) · Journal of Fungi · doi:10.3390/jof10040294 · Cited by 19
PET imaging of Aspergillus infection using Zirconium-89 labeled anti-β-glucan antibody fragments
Lai, J., Shah, S., Martínez‐Orengo, N., Knight, R., Alemu, E., Turner, M. L., Wang, B., Lyndaker, A., Shi, J., Basuli, F., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06760-4 · Cited by 10
“Aspergillus fumigatus ( A. fumigatus ) is the most common IFI pathogen, affecting over 250,000 patients annually [3].”
BackgroundKordyl, O., Styrna, Z., Wojtyłko, M., Michniak‐Kohn, B. B., & Osmałek, T. Z. (2024) · Microbes and Infection · doi:10.1016/j.micinf.2024.105426 · Cited by 13
An Estimate of Severe and Chronic Fungal Diseases in the Republic of Kazakhstan
Kemaykin, V., Tabinbaev, N., Khudaibergenova, M. S., Olifirovich, A., Abdrakhmanova, L., Denning, D. W., & Климко, Н. Н. (2018) · Journal of Fungi · doi:10.3390/jof4010034 · Cited by 11
“29/100,000 population), and correspond to Uzbekistan, Ukrainian and mean European parameters [5,18,20,21].”
BackgroundMethodInfluentialSelf-citationFrom culturomics to metagenomics: the mycobiome in chronic respiratory diseases
Vandenborght, L., Enaud, R., Coron, N., Denning, D. W., & Delhaès, L. (2019) · European Respiratory Society eBooks · doi:10.1183/2312508x.10015918 · Cited by 12
Self-citationIncidence of ICU-Acquired Candidemia in a Tertiary Care Hospital in Cairo, Egypt
Abass, E., Mohamed, S., El-Kholy, I. M. A., & ZAKI, S. M. (2019) · Egyptian Journal of Microbiology · doi:10.21608/ejm.2019.14099.1104 · Cited by 12
“The highest incidence rate per 1,000 ICU admissions previously reported was 34.3 episodes and the highest country burden of candidemia was 21 episodes per 100,000 inhabitants (González de Molina et al., 2012 and Bongomin et al., 2017).”
BackgroundInfluentialGuenter, S., Gorkiewicz, G., Halwachs, B., Kashofer, K., Thueringer, A., Wurm, P., Zollner‐Schwetz, I., Valentin, T., Prattes, J., Wunsch, S., et al. (2020) · Journal of Fungi · doi:10.3390/jof6020043 · Cited by 10
Buil, J. B., Brüggemann, R. J. M., Denardi, L. B., Melchers, W. J. G., & Verweij, P. E. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa185 · Cited by 10
Liston, S. D., Whitesell, L. J., McLellan, C. A., Mazitschek, R., Petraitis, V., Petraitienė, R., Kavaliauskas, P., Walsh, T. J., & Cowen, L. E. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00899-20 · Cited by 13
Monogenetic causes of fungal disease: recent developments
Zhang, Y., Li, R., & Wang, X. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.09.002 · Cited by 12
Khan, A. A., Alanazi, A. M., Alsaif, N. A., Algrain, N., Wani, T. A., & Bhat, M. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030333 · Cited by 11
“5 million people are affected by a fungal infection each year [1].”
BackgroundSantos, F. J. P.-D. L., García-Ortega, L. F., Robledo-Márquez, K., Guzmán-Moreno, J., & Riego‐Ruiz, L. R. (2021) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2012.12034 · Cited by 10
“Some of the fungal species recognized as causing agents of candidemia in nosocomial infections are Candida albicans, Candida parapsilosis and Candida glabrata [2, 3].”
BackgroundInducible Selectable Marker Genes to Improve Aspergillus fumigatus Genetic Manipulation
Baldin, C., Kühbacher, A., Merschak, P., Sastré-Velásquez, L. E., Abt, B., Dietl, A., Haas, H., & Gsaller, F. (2021) · Journal of Fungi · doi:10.3390/jof7070506 · Cited by 10
“fumigatus is also known to affect immunocompetent individuals, inducing chronic and allergic diseases [1].”
BackgroundGenetic Analyses of Amphotericin B Susceptibility in Aspergillus fumigatus
Fan, Y., Korfanty, G. A., & Xu, J. (2021) · Journal of Fungi · doi:10.3390/jof7100860 · Cited by 15
“It is estimated that over 300,000 cases of invasive aspergillosis occur annually, with ~10 million at risk [5].”
BackgroundGoyeneche-García, A., Rodríguez-Oyuela, J., Sánchez, G., & Firacative, C. (2021) · Journal of Fungi · doi:10.3390/jof7121092 · Cited by 11
“Even though mortality rate in IA patients can exceed 90% of cases [4], most of the patients in our study survived (84.”
BackgroundResultBrito, P. K. M. O., de Campos, G. Y., Guimarães, J. G., da Costa, L. S., de Moura, E. S., Chica, J. E. L., Roque‐Barreira, M. C., & da Silva, T. A. (2022) · Vaccines · doi:10.3390/vaccines10040620 · Cited by 9
“According to the Global Action Fund for Fungal Infections, the genus Cryptococcus has been responsible for clinical cases of cryptococcosis, which has highly impacted global public health over the last several decades [3,4].”
BackgroundSaveleva, М. S., Ленгерт, Е. В., Verkhovskii, R. A., Abalymov, A. A., Pavlov, A. M., Ermakov, A. V., Сергеевна, П. Е., Штыков, С. Н., & Svenskaya, Y. I. (2022) · Biomaterials Science · doi:10.1039/d2bm00539e · Cited by 11
Qadri, H., Shah, A. H., Mir, M. A., Qureshi, M. F., & Prasad, R. (2022) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2022.103713 · Cited by 12
Dutra, J. A. P., Maximino, S. C., Gonçalves, R. D. C. R., Morais, P. A. B., Silva, W. C. D. L., Rodrigues, R. P., Neto, Á. C., Lacerda, V., Borges, W. D. S., & Kitagawa, R. R. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14131 · Cited by 12
“It is responsible for millions of mucocutaneous (mouth, vagina, and intestine) fungal infections, about 750,000 cases of systemic infections, and an annual mortality rate of 71% (Gudlaugsson et al., 2003; Bongomin et al., 2017; Global Action Fund For Fungal Infections (GAFFI), 2015).”
BackgroundAlves-Silva, J. M., Cocco, E., Piras, A., Gonçalves, M. J., da Silva, A. B. G., Falconieri, D., Porcedda, S., Cruz, M. T., Maxia, A., & Salgueiro, L. (2023) · Plants · doi:10.3390/plants12020359 · Cited by 13
“Immunocompromised individuals are more prone to fungal infections [1], being Candida and Cryptococcus two main etiological agents for invasive infections [1,2].”
BackgroundEchinocandin exposures in obese patients: A scoping review and clinical perspectives
Alsowaida, Y. S., Alamer, A., Thabit, A. K., Almulhim, A., Aleissa, M. M., Kalbasi, A., Eljaaly, K., Almangour, T. A., & Erstad, B. L. (2023) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxad021 · Cited by 10
Insights into the global emergence of antifungal drug resistance
Boyce, K. J., Morrissey, O., Idnurm, A., & Macreadie, I. G. (2019) · Microbiology Australia · doi:10.1071/ma19024 · Cited by 10
Nucleoside selectivity of Aspergillus fumigatus nucleoside‐diphosphate kinase
Nguyen, S. A., Jovcevski, B., Pukala, T. L., & Bruning, J. B. (2020) · FEBS Journal · doi:10.1111/febs.15607 · Cited by 10
Invasive pulmonary aspergillosis in the ICU: the corticosteroid link
Terrones-Campos, C., Gallardo‐Pizarro, A., Martínez-Urrea, A., Castiella, A., Vergara, A., Gonzalez, A., Egri, N., & García‐Vidal, C. (2026) · Pneumonia · doi:10.1186/s41479-025-00189-5 · Cited by 13
“The global burden of IPA is likely underestimated, with current estimates exceeding 300,000 cases annually [1].”
Role of fine‐needle aspiration cytology in early diagnosis of fungal infections
George, B., Rolon, M. D. M. R., & Clement, C. G. (2020) · Diagnostic Cytopathology · doi:10.1002/dc.24447 · Cited by 9
“K E YWORD S fine needle aspiration cytology, fungal infections, immunocompromised 1 | INTRODUCTION The incidence and severity of opportunistic infections has increased over the last decades due to the rise in the number of patients with immunocompromised conditions such as AIDS, organ transplantation, and cancer chemo…”
BackgroundRocha, M. C., Fabri, J. H. T. M., Silva, L. P., Angolini, C. F. F., Bertolini, M. C., da Cunha, A. F., Valiante, V., Goldman, G. H., Fill, T. P., & Malavazi, I. (2021) · Genetics · doi:10.1093/genetics/iyab036 · Cited by 11
Wells, K. M., Ciftci, Y., Peddinti, B. S. T., Ghiladi, R. A., Vediyappan, G., Spontak, R. J., & Govind, R. (2023) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2023.08.088 · Cited by 9
Development of a novel mycobiome diagnostic for fungal infection
Weaver, D., Frazer, L. N., Palmer, M., Richardson, M. D., Bromley, M., & Bowyer, P. (2024) · BMC Microbiology · doi:10.1186/s12866-024-03197-5 · Cited by 13
“Fungal infections affect over a billion people and kill an estimated 1.5 million annually [1].”
BackgroundMethodInfluentialSWI/SNF complex-mediated chromatin remodeling in Candida glabrata promotes immune evasion
Kumar, K., Pareek, A., & Kaur, R. (2024) · iScience · doi:10.1016/j.isci.2024.109607 · Cited by 11
Gómez-Gaviria, M., & Mora-Montes, H. M. (2024) · Carbohydrate Research · doi:10.1016/j.carres.2024.109220 · Cited by 9
Magic-angle spinning NMR spectral editing of polysaccharides in whole cells using the DREAM scheme
Delcourte, L., Berbon, M., Rodriguez, M., Subban, K., Lends, A., Grélard, A., Morvan, E., Habenstein, B., Saupe, S. J., Delhaès, L., et al. (2024) · Methods · doi:10.1016/j.ymeth.2024.07.003 · Cited by 10
Recent advances in the clinical development of antifungal vaccines: a narrative review
Alapan, D., Bisweswar, O., Prasenjit, S., Prasanjit, D., & Bandyopadhyay, A. (2024) · Frontiers in Tropical Diseases · doi:10.3389/fitd.2024.1446477 · Cited by 11
Rai, M. N., Lan, Q., Parsania, C., Rai, R., Shirgaonkar, N., Chen, R., Shen, L., Tan, K., & Wong, K. H. (2024) · eLife · doi:10.7554/elife.73832 · Cited by 12
“Candida species are prominent opportunistic fungal pathogens with an associated mortality rate of ~30–60% among immunocompromised populations ( Bongomin et al., 2017 ; Lamoth et al., 2018 ).”
BackgroundTian, Y., Wang, S., Ma, Y.-C., Li, Y., Li, R., Fu, Y., Zhang, R., Zhu, R., & Zhao, F. (2024) · Microbial Cell Factories · doi:10.1186/s12934-024-02577-w · Cited by 10
“Fungal infections pose a significant medical threat to human health, leading to millions of deaths worldwide each year [1, 2].”
Akwongo, B., Kakudidi, E. K., Nsubuga, A. M., Andama, M., Namaganda, M., Tugume, P., Asiimwe, S., Anywar, G., & Katuura, E. (2024) · Tropical Medicine and Health · doi:10.1186/s41182-024-00628-x · Cited by 17
“Globally it is estimated that, 1.5 million people die from invasive fungal infections annually [1].”
InfluentialEnriching the future of public health microbiology with hybridization bait capture
Beaudry, M. S., Bhuiyan, M. I. U., & Glenn, T. C. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00068-22 · Cited by 11
“However, the true burden of fungal disease is still unknown, as the methodology to detect fungal infections is not universal (79).”
InfluentialHoulder, E. L., Gago, S., Vere, G., Furlong-Silva, J., Conn, D. P., Hickey, E., Khan, S., Thomson, D. D., Shepherd, M. W., Lebedinec, R., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.10.040 · Cited by 10
“1-4 At least 10 million people worldwide display signifi-cant sensitivity to Af, which increases asthma severity 5 and can lead to the development of debilitating chronic fungal infections 6,7 such as allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.”
Self-citationBadran, M. M., Alsubaie, A., Salem-Bekhit, M. M., Alomrani, A. H., Almomen, A. A., Ibrahim, M. A., & Alshora, D. H. (2024) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2024.102208 · Cited by 14
“For instance, fungal keratitis causes an inflammation of the cornea due to fungal infection, which may cause corneal epithelial damage and stromal inflammation (Bongomin et al., 2017), which could lead to corneal scarring and visual impairment.”
Schwarz, M. C. R., Moskaluk, A. E., Daniels, J. B., VandeWoude, S., & Reynolds, M. M. (2024) · Journal of Fungi · doi:10.3390/jof10120829 · Cited by 12
“This is similar in scale to the mortality rate of tuberculosis, and three times greater than that of malaria [3].”
Lee, B. G., Jeong, K., Kim, H. E., & Yeo, M. (2025) · Environmental Pollution · doi:10.1016/j.envpol.2025.125684 · Cited by 10
Schirmer, H., Henriques, C., Simões, H., et al. (2025) · Pathogens · doi:10.3390/pathogens14020115 · Cited by 9
“Nearly a billion people are estimated to have skin, nail, and hair fungal infections [1], and this condition is the most common cause of skin disease in the European population [2].”
Lipid droplets restrict phagosome formation in antifungal immunity
Sun, W., Wu, H., Zhao, G., Shui, Q., Zhang, L., Luan, X., Chen, T., Liu, F., Zheng, Y., Zhao, W., et al. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01282-x · Cited by 11
Bermúdez-Puga, S., Mendes, B. D. S., Ramos-Galarza, J. P., de Azevedo, P. O. D. S., Converti, A., Molinari, F., Moore, S. J., Almeida, J. R., & Oliveira, R. P. D. S. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108605 · Cited by 9
Chen, Y., Dhillon, S., Adomakoh, N., & Roberts, J. A. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2025.2539427 · Cited by 9
“Asia likely has the highest burden of IFIs, with 50% (78,778 cases) of the global cases of candidemia reportedly occurring in 10 Asian countries [13].”
Seo, S., Park, J. W., Han, D., et al. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11120673 · Cited by 9
“Moreover, almost a billion people are estimated to have skin, nail and hair fungal infections, several tens of millions of people have mucosal candidiasis, and more than 150 million people have serious fungal diseases, which are fatal or significantly affect quality of life [16].”
BackgroundSchulz, J., Michelet, R., Joseph, J. F., et al. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114551 · Cited by 9
Radonicic, V., Yvanoff, C., Villalba, M. I., Kasas, S., & Willaert, R. (2022) · Fermentation · doi:10.3390/fermentation8050195 · Cited by 10
Steffen, H. C., Bosch, C., Wolfaardt, G. M., & Botha, A. (2022) · Water SA · doi:10.17159/wsa/2022.v48.i2.3918 · Cited by 14
The GARP complex is required for filamentation in Candida albicans
Hossain, S., Robbins, N., & Cowen, L. E. (2022) · Genetics · doi:10.1093/genetics/iyac152 · Cited by 9
Aissat, F. Z., & Denning, D. W. (2023) · Mycoses · doi:10.1111/myc.13585 · Cited by 8
Self-citationBrito, S. C. P., Pinto, M. R., Alcântara, L. M., et al. (2023) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0010865 · Cited by 9
“However, research and funding investments still do not turn into improvements for relief of the relative disability of skin diseases [1], therefore considered a public health problem [2].”
BackgroundIdentification of effective plant extracts against candidiasis: an in silico and in vitro approach
Bhairavi, V. A., Vidya, S. L., & Sathishkumar, R. (2023) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-023-00489-x · Cited by 13
Bielec, F., Wenecka, M., Brauncajs, M., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196270 · Cited by 9
“in the pathogenesis of various diseases is increasing, especially in critically ill patients [5].”
BackgroundReview on pharmacology activities of Justicia Gendarussa Burm F.
Jain, T., Singh, M. P., Bhardwaj, H., & Gohil, K. J. (2023) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2023.100339 · Cited by 9
Antifungal Resistance and Genotyping of Clinical Candida parapsilosis Complex in Japan
Khalifa, H. O., Watanabe, A., & Kamei, K. (2023) · Journal of Fungi · doi:10.3390/jof10010004 · Cited by 10
“According to a recent estimate, fungal infection affects over a billion people and kills more than 1.5 million per year, which is similar to the outcomes of tuberculosis and is more than three-fold greater than the rates caused by malaria [2].”
BackgroundInfluentialAntifungal activity of the repurposed drug disulfiram against Cryptococcus neoformans
Peng, M., Zhang, C., Duan, Y.-Y., Liu, H.-B., Peng, X.-Y., Wei, Q., Chen, Q.-Y., Sang, H., & Kong, Q.-T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1268649 · Cited by 9
(2024) · doi:10.1128/spectrum.02594-23 · Cited by 10
Rinker, D. C., Sauters, T. J. C., Steffen, K., Gumilang, A., Raja, H. A., Rangel‐Grimaldo, M., Pinzan, C. F., de Castro, P. A., dos Reis, T. F., Delbaje, E., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06756-8 · Cited by 14
“The deadliest infections are invasive in nature, with pulmonary aspergillosis being the most common and most deadly type 5 .”
BackgroundCorzo-León, D., Perales-Martínez, D., Martin‐Onraët, A., Rivera-Martínez, N. E., Camacho-Ortíz, A., & Villanueva‐Lozano, H. (2018) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2018.10.277 · Cited by 9
Chennell, P., Yessaad, M., Abd-El-Kader, F., Jouannet, M., Wasiak, M., Bouattour, Y., & Sautou, V. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090786 · Cited by 10
“It has been estimated that 1,000,000 cases occur annually in the world, but as it is often under-suspected, it is also underdiagnosed and real numbers might be a lot higher [3].”
BackgroundBreath analysis for respiratory infections
Davis, C. E., Hill, J. E., Frank, M. A., McCartney, M. M., Schivo, M., & Bean, H. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819967-1.00021-9 · Cited by 9
“As the incidences of these risk factors and comorbidities are rising globally, so too are the incidences of fungal infections.(25)”
BackgroundInfluentialDetection and Control of Fungal Outbreaks
Cáceres, D. H., Tap, R. M., Alastruey‐Izquierdo, A., & Hagen, F. (2020) · Mycopathologia · doi:10.1007/s11046-020-00494-1 · Cited by 13
Human Fungal Infections in Kuwait—Burden and Diagnostic Gaps
Alfouzan, W. A., Al-Wathiqi, F., Altawalah, H., Asadzadeh, M., Khan, Z., & Denning, D. W. (2020) · Journal of Fungi · doi:10.3390/jof6040306 · Cited by 9
“Fungal infections have long been considered of little importance to public health because most are not transmissible (Pneumocystis and dermatophytes being exceptions), and antifungal resistance has been until recently a relatively minor problem [1].”
BackgroundInfluentialSelf-citationEpidemiological Attributes of Candida Species in Tropical Regions
Bohner, F., Gácser, A., & Tóth, R. (2021) · Current Tropical Medicine Reports · doi:10.1007/s40475-021-00226-5 · Cited by 11
“Dermatomycosis cases in Brazil were also studied between 1996 and 2011. According to the findings, 4815 of the 38,520 fungal infections were linked to the genus Candida (12.5%), which corresponds with previous studies observing high incidences of fungal dermal infections in warmer climate zones. This data further stre…”
BackgroundInfluentialOttaviano, E., Borghi, E., Giovati, L., Falleni, M., Tosi, D., Magliani, W., Morace, G., Conti, S., & Ciociola, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010904 · Cited by 9
Radaković, N., Nikolić, A., Terzić, N., Stojković, P., Stankovic, N., Šolaja, B. A., Opsenica, I., & Pavić, A. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114137 · Cited by 10
The role of properdin and Factor H in disease
Cortés, C., Desler, C., Mazzoli, A., Chen, J. Y., & Ferreira, V. P. (2022) · Advances in immunology · doi:10.1016/bs.ai.2021.12.001 · Cited by 10
Current situation of fungal diseases in Eritrea
Werkneh, S., Orefuwa, E., & Denning, D. W. (2022) · Mycoses · doi:10.1111/myc.13474 · Cited by 8
“Among African countries, Nigeria is the leading country followed by Uganda and Kenya in terms of the burden of CPA.60 The unavailability of Aspergillus IgG antibody detection means several cases might be misdiagnosed and mistreated, as respiratory fungal culture infrequently yields Aspergillus.”
BackgroundInfluentialSelf-citationEpidemiology and clinical outcomes of microbial keratitis in South East Nepal: a mixed-methods study
Puri, L. R., Burn, H., Roshan, A., Biswakarma, R., & Burton, M. J. (2022) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2022-001031 · Cited by 9
Gong, Y., Li, H., Wu, F., Li, Y., & Zhang, S. (2022) · Biomolecules · doi:10.3390/biom12070965 · Cited by 9
“5 million deaths each year globally [1].”
Mendoza, S. R., Liedke, S. C., Noval, C., Ferreira, M. D. S., Gomes, K. X., Honorato, L., Nimrichter, L., Peralta, J. M., & Guimaraes, A. J. (2022) · Medical Mycology · doi:10.1093/mmy/myac050 · Cited by 10
Rahman, S., van Rhijn, N., Papastamoulis, P., Thomson, D. D., Carter, Z., Gregson, L., Fortune‐Grant, R., Rattray, M., Bromley, J. M., & Bignell, M. E. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.907519 · Cited by 9
Jusuf, S., Zhan, Y., Zhang, M., Alexander, N. J., Viens, A. L., Mansour, M. K., & Cheng, J. (2022) · Photochemistry and Photobiology · doi:10.1111/php.13719 · Cited by 9
“Fungal pathogens have emerged as a severe global health risk, estimated to be responsible for over 150 million cases of severe infections and 1.7 million deaths annually (1).”
BackgroundInfluentialAntifungal Compounds from the Leaves of Rhynchosia minima
Adewole, A. H., Famuyide, I. M., McGaw, L. J., Selepe, M. A., & October, N. (2022) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200837 · Cited by 10
“Invasive fungal infections (IFIs) are a scourge to human health as they result in high rates of morbidity and mortality.[1,2] Candida and Cryptococcus species are the leading causes of these infections.”
BackgroundFenley, J. D. C., de Barros, P. P., do Carmo, P. H. F., Garcia, M. T., Rossoni, R. D., & Junqueira, J. C. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44110364 · Cited by 10
Oliveira, M., Pinto, M., Simões, H., Gomes, J. P., Veríssimo, C., & Sabino, R. (2022) · Infectious Diseases Now · doi:10.1016/j.idnow.2022.11.002 · Cited by 10
“Recent data estimates that approximately 3 million people suffer from chronic pulmonary aspergillosis (CPA) worldwide [1].”
Robertson, E., Abera, C., Wood, K., Deressa, K., Mesfin, S., & Scantlebury, C. E. (2023) · PLoS ONE · doi:10.1371/journal.pone.0278964 · Cited by 10
“5 million people annually and affecting over a billion people worldwide [6].”
BackgroundLertsuphotvanit, N., Tuntarawongsa, S., Jitrangsri, K., & Phaechamud, T. (2023) · Gels · doi:10.3390/gels9050412 · Cited by 9
“species have increased because of the escalation in HIV infection and the acquired immune deficiency syndrome (AIDS) epidemic [1,2].”
BackgroundBiology and Function of Exo-Polysaccharides from Human Fungal Pathogens
Chung, K. Y., & Brown, J. C. S. (2020) · Current Clinical Microbiology Reports · doi:10.1007/s40588-020-00137-5 · Cited by 10
Hunsaker, E. W., McAuliffe, K. J., & Franz, K. J. (2020) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-020-01796-x · Cited by 13
Molecular epidemiology of Candida tropicalis isolated from urogenital tract infections
Wang, Q., Li, C., Tang, D., & Tang, K. (2020) · MicrobiologyOpen · doi:10.1002/mbo3.1121 · Cited by 9
“…resistance, Candida tropicalis, epidemiology, multilocus sequence typing, urogenital tract infection In recent years, the proportion of urinary tract infections caused by Candida has increased, especially in critically ill patients (Bongomin et al., 2017; Fisher, 2011; Gharanfoli et al., 2019).”
BackgroundCarbohydrate Specificity of Antibodies against Phytopathogenic Fungi of the Aspergillus Genus
Krylov, V. B., Петрук, М. И., Глушко, Н. И., Khaldeeva, E. V., Мокеева, В. Л., Биланенко, Е. Н., Lebedin, Y. S., Еремин, С. А., & Nifantiev, N. E. (2018) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683818050095 · Cited by 10
Editorial: Antifungal Pipeline: Build It Strong; Build It Better!
Perfect, J. R., Krysan, D. J., Poeta, M. D., Selmecki, A. M., Brown, J. C. S., & Cowen, L. E. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.881272 · Cited by 7
Functionalized lipid-based drug delivery nanosystems for the treatment of human infectious diseases
de Camargo, B. A. F., Fonseca‐Santos, B., Carvalho, S. G., Carvalho, G. C., Filippo, L. D. D., Araújo, V. H. S., Duarte, J. L., Silvestre, A. L. P., Bauab, T. M., & Chorilli, M. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2047007 · Cited by 8
“The increase in infections rates caused by fungi has come to the attention of researchers, especially related to immunocompromised patients such as HIV-positive, transplanted, and undergoing chemotherapy (Vallabhaneni et al. 2016; Bongomin et al. 2017).”
BackgroundNeuroimmune Responses in a New Experimental Animal Model of Cerebral Aspergillosis
Sullivan, B. N., Baggett, M. A., Guillory, C., Jones, M., & Steele, C. H. (2022) · mBio · doi:10.1128/mbio.02254-22 · Cited by 8
Macropinocytosis as a potential mechanism driving neurotropism of Cryptococcus neoformans
Lanser, D. M., Bennett, A. B., Vu, K., & Gelli, A. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1331429 · Cited by 8
Bharti, S., Singh, B., Kumar, S., Kumar, R., & Kumar, J. (2024) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-024-03928-w · Cited by 8
“Invasive candidiasis is the utmost and common hospital-acquired infection in many countries, with a global prevalence of 2.5 to 7.0 lacs subjects per year, and a mortality rate ranging from 40 to 55% (Kullberg and Arendrup 2015; Bongomin et al. 2017; Logan et al. 2020).”
InfluentialIyadorai, T., Tay, S. T., Liong, C. C., Samudi, C., Chow, L. C., Cheong, C. S., Velayuthan, R. D., Tan, S. M., & Gan, G. G. (2024) · Epidemiologic Reviews · doi:10.1093/epirev/mxae003 · Cited by 9
Fungal vaccines and adjuvants: a tool to reveal the interaction between host and fungi
Wang, Z., & Shao, J. (2024) · Archives of Microbiology · doi:10.1007/s00203-024-04010-7 · Cited by 11
“…for example, skin, hair, nails and eyes, affect about 1 billion people worldwide, the yearly oral and vaginal mucosal fungal infections influence approximate 135 million people around the world, and allergic fungal infections endanger nearly 23.3 million population (Bongomin et al. 2017).”
InfluentialLiu, Y., Yu, S., He, Y., Zhang, S., Liu, M., Han, J., & Sun, B. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01057 · Cited by 10
Simulation of azole drugs’ solubility in mono and binary systems at different temperatures
Babaei, M., Rahimpour, E., Mohammadian, E., et al. (2024) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2024.125695 · Cited by 8
Bruch, A., Lazarova, V., Berg, M., Krüger, T., Schäuble, S., Kelani, A. A., Mertens, B., Lehenberger, P., Kniemeyer, O., Kaiser, S., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae1205 · Cited by 11
Chatur, V. M., Dhole, S. N., Kulkarni, N. S., et al. (2024) · Chemical Physics Impact · doi:10.1016/j.chphi.2024.100801 · Cited by 8
Piccioni, A., Spagnuolo, F., Baroni, S., Savioli, G., Valletta, F., Bungaro, M. C., Tullo, G., Candelli, M., Gasbarrini, A., & Franceschi, F. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm15010005 · Cited by 9
Ullah, A., Ali, F., Ullah, F., Sadozai, S. K., Khan, S. A., Hussain, S., Alrefaei, A. F., & Ali, S. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010125 · Cited by 9
“Fungal infections are among the most prevalent global health issues, with over a billion individuals suffering from skin, nail, and hair mycoses, particularly in less-developed nations [1,2].”
Spagnolo, A. M. (2025) · Hygiene · doi:10.3390/hygiene5010003 · Cited by 9
“Fungal agents are responsible for at least 13 million infections and 1.5 million deaths per year globally, mainly in individuals with compromised immune function [7,8].”
InfluentialBashera, M. A., Moulick, S. P., Islam, M. B., Jahan, F., Uddin, M. N., Rana, G. M. M., Hasan, M. S., Rahman, M. M., Moniruzzaman, M., Dey, S. S., et al. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42901 · Cited by 10
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.